Benjamin Stillman, DO
Family Medicine · Petersburg, INNPI 1164942207
Payments from drug & device makers
Across 296 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$778
- Otsuka America Pharmaceutical, Inc.$412
- AstraZeneca$403
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$269
- Idorsia Pharmaceuticals US Inc$256
- Novo Nordisk$248
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,633100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $778 |
| Otsuka America Pharmaceutical, Inc. | 24 | $412 |
| AstraZeneca | 17 | $403 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $269 |
| Idorsia Pharmaceuticals US Inc | 13 | $256 |
| Novo Nordisk | 16 | $248 |
| Corium, LLC | 16 | $243 |
| Ironshore Pharmaceuticals Inc. | 14 | $227 |
| Amgen | 13 | $226 |
| Lilly USA, LLC | 14 | $219 |
| Bayer | 10 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $173 |
| Merck | 10 | $159 |
| Pfizer | 7 | $121 |
| Supernus Pharmaceuticals, Inc. | 5 | $96 |
| Axsome Therapeutics, Inc. | 5 | $85 |
| Novartis | 6 | $84 |
| Abbott | 3 | $48 |
| Sumitomo Pharma America, Inc. | 3 | $46 |
| Lundbeck LLC | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 3 | $39 |
| Collegium Pharmaceutical, Inc. | 2 | $33 |
| Exact Sciences | 2 | $27 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Ardelyx, Inc. | 1 | $18 |
| Alkermes, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,633 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $59,903 |
| RexultiBrexpiprazole | 24 | $35,659 |
| JanuviaSitagliptin Phosphate | 39 | $33,289 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $29,166 |
| JardianceEmpagliflozin | 19 | $26,979 |
| EliquisApixaban | 46 | $26,144 |
| VraylarCariprazine Hcl | 15 | $25,311 |
| XareltoRivaroxaban | 23 | $24,945 |
| LinzessLinaclotide | 28 | $21,628 |
| RybelsusSemaglutide | 17 | $17,231 |
| TrulicityDulaglutide | 13 | $16,847 |
| TrintellixVortioxetine Hydrobromide | 30 | $14,238 |
| UbrelvyUbrogepant | 13 | $14,220 |
| QuliptaAtogepant | 12 | $13,876 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,920 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess, Ubrelvy, Qulipta, Synthroid | $778 | $77,290104 claims |
| Novo NordiskOzempic, Rybelsus | $248 | $77,13477 claims |
| MerckJanuvia, Belsomra | $159 | $40,40152 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $412 | $35,65924 claims |
| Boehringer IngelheimJardiance | $14 | $26,97919 claims |
| PfizerEliquis | $121 | $26,14446 claims |
| Lilly USA, LLCTrulicity | $219 | $16,84713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $173 | $14,23830 claims |
| AstraZenecaBreztri Aerosphere | $403 | $11,92019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Petersburg
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.